Surgery Partners
Surgery Partners' revenue rose 6.2% to $3.3 billion in fiscal 2025. Its operating margin was 11.8%, up from 11.2% a year earlier. Free cash flow was $196 million, down 6.7%. The diluted share count rose 0.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Surgery Partners does
Surgery Partners owns and runs surgical centers across the United States. Its sites include ambulatory surgery centers (outpatient facilities where patients have an operation and go home the same day), short-stay surgical hospitals and physician practices. Most of its work is planned, non-emergency surgery in fields such as orthopedics and pain management, eye care, and stomach and bowel procedures.
It makes money from fees for the care given at its facilities, paid by insurers, government programs such as Medicare, and patients. It reports one segment, Surgical Facilities, which supplies nearly all of its revenue. The surgery centers and hospitals alone brought in approximately $3.2 billion in 2025. Doctors are often partial owners of its facilities, and the company seeks to be the partner for physicians who want to stay independent.
It operates more than 200 locations in 30 states. At the end of 2025 it owned or operated 157 ambulatory surgery centers and 19 surgical hospitals. It grows by recruiting physicians, adding services and buying more facilities.
Its biggest risks, as it describes them
- Its facilities do not meet the safe harbors of the federal Anti-Kickback Statute, so a change in how regulators read it could bring penalties.
- Cuts or changes in what Medicare, other government programs and insurers pay could reduce its revenue.
- Changes in health care rules may force it to buy out physician partners or renegotiate its agreements with them.
- Malpractice claims, audits and investigations could lead to large payments or lost revenue.
- Federal law limits how much its surgical hospitals can expand.
Income statement
Surgery Partners lost money in fiscal 2025: a net loss of $78 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 390 | 283 | 196 | 270 | 240 |
| Debt incl. finance leases | 3,323 | 3,220 | 3,497 | 4,203 | 4,671 |
| Net debt (negative means net cash) | 2,933 | 2,937 | 3,302 | 3,934 | 4,431 |
| Net debt to EBITDA | 7.3x | 6.4x | 7.4x | 7.8x | 7.8x |
| Debt to equity | 3.0x | 1.6x | 1.8x | 2.4x | 2.7x |
| Interest coverage | 1.6x | 1.6x | 1.9x | 1.8x | 1.5x |
| Current ratio | 1.8x | 1.9x | 1.7x | 1.8x | 1.9x |
| Quick ratio | 1.6x | 1.7x | 1.6x | 1.6x | 1.7x |
Cash flow
Projections
Project Surgery Partners' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $143,500 of Surgery Partners shares on the open market, and 6 insiders sold $1.3 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Teresa DeLucaDirector | Bought | 10,000 | $14.35 | $143,500 | Form 4 |
| Mar 16, 2026 | Jason Eric EvansChief Executive Officer | Sold | 20,400 | $12.47 | $254,388 | Form 4 |
| Mar 16, 2026 | David T DohertyChief Financial Officer | Sold | 8,867 | $12.50 | $110,838 | Form 4 |
| Mar 13, 2026 | Marissa BrittenhamChief Strategy Officer | Sold | 3,657 | $12.54 | $45,859 | Form 4 |
| Mar 13, 2026 | Danielle BurkhalterChief Human Resources Officer | Sold | 3,469 | $12.83 | $44,507 | Form 4 |
| Mar 12, 2026 | Jennifer BaldockChief Admin & Dev Officer | Sold | 5,798 | $13.17 | $76,360 | Form 4 |
| Mar 6, 2026 | David T DohertyChief Financial Officer | Sold | 14,574 | $13.84 | $201,704 | Form 4 |
| Mar 6, 2026 | Jason Eric EvansChief Executive Officer | Sold | 11,462 | $13.79 | $158,061 | Form 4 |
| Mar 6, 2026 | Jennifer BaldockChief Admin & Dev Officer | Sold | 10,082 | $13.70 | $138,123 | Form 4 |
| Mar 6, 2026 | Marissa BrittenhamChief Strategy Officer | Sold | 8,785 | $13.70 | $120,354 | Form 4 |
| Mar 6, 2026 | Danielle BurkhalterChief Human Resources Officer | Sold | 7,736 | $13.60 | $105,210 | Form 4 |
| Mar 6, 2026 | William Trenton WebbAmerican Group President | Sold | 272 | $13.93 | $3,789 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 8 | 4 of 8 | 4 of 8 |
| Rule of 40 | 15.5% | 20.3% | 12.2% |
| Altman Z'' | 1.23 | 1.12 | 1.09 |
| Accruals ratio | −4.5% | −6.3% | −4.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 3 of 8 | 4 of 8 | 4 of 8 |
Compare
Put Surgery Partners side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Surgery Partners | FY25 | 6.2% | 11.8% | 5.9% | 4.2% | 7.8x | 4 | |
| Acadia Healthcare | FY25 | 5.0% | — | −13.3% | −16.0% | — | 4 | Compare |
| Brookdale Senior Living | FY25 | 2.2% | 0.4% | 0.5% | 0.3% | 10.5x | 4 | Compare |
| Astrana Health | FY25 | 56.4% | 2.5% | 3.3% | 4.2% | 4.9x | 4 | Compare |
| Ensign Group | FY25 | 18.7% | 8.4% | — | 19.7% | −0.8x | 6 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1,145 | — | 1,772 | 1,831 | 1,860 | 2,225 | 2,539 | 2,743 | 3,114 | 3,309 |
| Revenue growth | 19.3% | — | — | 3.4% | 1.6% | 19.6% | 14.1% | 8.0% | 13.5% | 6.2% |
| Gross profit | 324 | — | 410 | 424 | — | — | — | — | — | — |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | 196 | — | 78 | 236 | 183 | 302 | 345 | 328 | 349 | 390 |
| Net income | 10 | — | −206 | −75 | −116 | −71 | −55 | −12 | −168 | −78 |
| Diluted EPS (US$) | 0.20 | — | −4.96 | −2.29 | −3.19 | −1.12 | −0.59 | −0.09 | −1.33 | −0.61 |
| Diluted shares (millions) | 48 | — | 48 | 48 | 49 | 72 | 92 | 126 | 126 | 127 |
| Cash flow | ||||||||||
| Cash from operations | 125 | — | 145 | 130 | 247 | 87 | 159 | 294 | 300 | 274 |
| Capital expenditure | 39 | — | 40 | 74 | 43 | 58 | 81 | 89 | 90 | 79 |
| Free cash flow | 86 | — | 105 | 56 | 204 | 30 | 78 | 205 | 210 | 196 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 146 | 0 | 107 | 14 | 105 | 286 | 146 | 80 | 379 | 162 |
| Stock-based compensation | 2 | — | 9 | 10 | 13 | 17 | 18 | 18 | 33 | 15 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 70 | 175 | 184 | 93 | 318 | 390 | 283 | 196 | 270 | 240 |
| Debt incl. finance leases | 1,474 | 2,186 | 2,354 | 2,850 | 3,158 | 3,323 | 3,220 | 3,497 | 4,203 | 4,671 |
| Total assets | 2,305 | 4,623 | 4,676 | 5,019 | 5,413 | 6,118 | 6,682 | 6,877 | 7,890 | 8,120 |
| Total liabilities | 1,980 | 3,286 | 3,577 | 4,036 | 4,531 | 4,148 | 3,741 | 3,842 | 4,694 | 4,988 |
| Shareholders' equity | 10 | 655 | 405 | 297 | 116 | 1,089 | 1,998 | 1,987 | 1,790 | 1,713 |
| Margins and ratios | ||||||||||
| Gross margin | 28.3% | — | 23.1% | 23.1% | — | — | — | — | — | — |
| Operating margin | 17.1% | — | 4.4% | 12.9% | 9.8% | 13.6% | 13.6% | 12.0% | 11.2% | 11.8% |
| Net margin | 0.8% | — | −11.6% | −4.1% | −6.2% | −3.2% | −2.1% | −0.4% | −5.4% | −2.4% |
| Free cash flow margin | 7.5% | — | 5.9% | 3.0% | 11.0% | 1.3% | 3.1% | 7.5% | 6.7% | 5.9% |
| Rule of 40 (growth + FCF margin) | 26.9% | — | — | 6.4% | 12.5% | 20.9% | 17.2% | 15.5% | 20.3% | 12.2% |
| Return on capital | 6.9% | — | 1.9% | 5.3% | 3.9% | 5.5% | 5.1% | 4.2% | 4.1% | 4.2% |
| Return on equity | — | — | −38.8% | −21.3% | — | −11.8% | −3.5% | −0.6% | −8.9% | −4.5% |
| Return on assets | 0.4% | — | −4.4% | −1.5% | −2.2% | −1.2% | −0.8% | −0.2% | −2.3% | −1.0% |
| Net debt to EBITDA | 6.0x | — | 14.9x | 8.8x | 10.2x | 7.3x | 6.4x | 7.4x | 7.8x | 7.8x |